Edgewise Therapeutics (EWTX) Cash Flow: Operating & Free Cash Flow

Edgewise Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Edgewise Therapeutics, Inc. (EWTX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Operating Activities
Net Income	-167.80	-133.81	-100.16	-67.64	-42.81	-17.12	-9.71
Depreciation & Amortization	2.27	2.29	1.73	0.54	0.27	0.19	0.12
Deferred Income Tax	0.00	0.00	0.00	0.00	-2.29	0.00	0.00
Stock Based Compensation	0.00	24.71	17.56	10.92	4.40	0.35	0.08
Change in Working Capital	-5.37	10.33	-1.56	4.09	4.63	1.95	0.33
Change in Accounts Payable	0.27	1.74	-0.09	0.05	2.65	0.52	0.28
Change in Other Working Capital	-5.65	3.07	-3.66	4.04	1.98	1.43	0.06
Other Operating Activities	27.09	-12.55	-9.52	-0.54	2.29	0.00	0.00
Net Cash from Operating Activities	-143.82	-109.03	-91.95	-52.64	-33.51	-14.63	-9.17
Investing Activities
Capital Expenditures	-0.26	-1.31	-5.75	-5.55	-0.67	-0.20	-0.18
Acquisitions	0.00	0.00	0.00	0.07	0.24	0.00	0.00
Purchases of Investments	-527.23	-477.06	-255.87	-292.39	-288.20	-24.18	0.00
Sales/Maturities of Investments	494.69	293.71	364.50	227.36	46.64	0.00	0.00
Other Investing Activities	0.00	0.00	0.00	-0.07	-0.24	0.00	0.00
Net Cash from Investing Activities	-32.79	-184.66	102.89	-70.58	-242.23	-24.38	-0.18
Financing Activities
Common Stock Issued	196.09	239.15	53.33	129.17	186.15	0.20	0.00
Other Financing Activities	0.00	-0.26	-0.17	-0.25	-0.12	120.28	24.80
Net Cash from Financing Activities	196.09	249.25	53.17	129.64	186.38	120.28	24.80
Summary
Net Change in Cash	19.48	-44.43	64.10	6.43	-89.35	81.26	15.45
Cash at Beginning of Period	41.67	86.10	21.99	15.57	104.92	23.65	8.20
Cash at End of Period	61.15	41.67	86.10	21.99	15.57	104.92	23.65
Free Cash Flow	-143.82	-110.34	-97.69	-58.18	-34.18	-14.84	-9.35

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Edgewise Therapeutics Cash Flow

What is Edgewise Therapeutics's free cash flow?

Edgewise Therapeutics had negative free cash flow of $143.82M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$143.82M minus $256.00K of capital expenditures.

How much does Edgewise Therapeutics spend on capital expenditures?

Edgewise Therapeutics spent $256.00K on capital expenditures in fiscal 2025, compared with $1.31M a year earlier.

Does Edgewise Therapeutics pay dividends or buy back shares?

Edgewise Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition